MRNA · News · 20260811N
Litigation Settlement Exposure
Moderna, Inc. · 2026-08-11 · Importance 64 · Surprise 42 · In source text
Moderna recently agreed to pay Arbutus Biopharma $178 million to settle a patent-infringement dispute involving intellectual property relevant to Moderna’s mRNA platform. The settlement represents a material litigation cash outflow exceeding the $4 million materiality threshold. Reporting indicated that Arbutus plans to return approximately $230 million to shareholders, but did not provide additional details on Moderna’s payment timing or accounting treatment.
Key facts
- Moderna paid a $178 million settlement to Arbutus Biopharma Corporation for patent infringement. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | -122.8% | Moderna paid a $178 million settlement to Arbutus Biopharma Corporation for patent infringement. |
| cash | negative | realized | — | Moderna paid a $178 million settlement to Arbutus Biopharma Corporation for patent infringement. |